Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting 2019
September 13 - 16, 2019; Philadelphia, Pennsylvania
September 13 - 16, 2019Philadelphia, Pennsylvania
EASD 2019A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio CredOn the heels of the DAPA-HF outcomes trial, DEFINE-HF shows adding the SGLT-2 inhibitor to standard meds improved other endpoints heart failure patients care about, whether or not they had diabetes.
Medscape Medical News, September 17, 2019
HFSA 2019Shock and Awe: ARNI for Acute HF May Be Safely Started in ICUSome patients in cardiogenic shock may transition from IV vasoactive agents to sacubitril/valsartan without going hypotensive, suggests a small case series; PA-pressure guidance was crucial.
Medscape Medical News, September 17, 2019
HFSA 2019Marijuana Use Linked to Improved Acute-HF Hospital SurvivalChronic cannabis use seemed to protect against in-hospital death and shorten length of stay in the observational study with propensity matching — but not in all types of heart failure.
Excess Polypharmacy a Risk in HF, but Illness the Whole Reason?There's something about low education level and low income that drives people into hyperpolypharmacy,' said a researcher.
'We think it might have something to do with how people access care.
Medscape Medical News, Sep 19, 2018
Lower Is Better for Natriuretic Peptides in Titrating HF MedsPushing therapy toward a specific natriuretic peptide target doesn't work for everyone and isn't guideline-recommended. Still,
reduced levels mean better clinical and echo outcomes, say researchers.
